Zealand Pharma at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Zealand Pharma brings 1 presentation to ObesityWeek 2026 in National Harbor, and exhibits at Booth 333, Suite 9. Its program addresses the role of amylin analogues in future obesity care.

OrganizationObesityWeek 2026 Attendance
Zealand Pharma
Søborg, Denmark
◇Bronze Sponsor
BiotechBronze Sponsor
Biotech developing peptide medicines for obesity and metabolic disease, including the amylin analogue petrelintide, partnered with Roche.
Booth
Exhibiting at Booth 333, Suite 9
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Talk
Sun Nov 15
11:45am–1:15pm
Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care
Reviews trial data on amylin analogues, which act through a different hormone pathway than GLP-1, as single or combination obesity treatments.
with UTHealth Houston, knownwell, Pennington Biomedical Research Center
Interventional and clinical studiesNutrition, diet and food

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Zealand Pharma

Tell us what you sell and we’ll find the people at Zealand Pharma most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction